Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Molecular Profiles, XenoGesis Collaborate

Published: Monday, August 04, 2014
Last Updated: Monday, August 04, 2014
Bookmark and Share
Partnership will support pharmaceutical and biotech drug developers during the pre-clinical and formulation development stage.

Molecular Profiles’ pharmaceutical development services will be supported by XenoGesis’ expertise in preclinical drug metabolism and pharmacokinetics (DMPK) to give clients a smarter route into formulation development and a better understanding of a compound’s bioavailability.

This strategic alliance will allow the Nottingham-based companies to help drug developers in the initial design and selection of compounds for key DMPK and ADME (absorption, distribution, metabolism and elimination) studies, as well as supporting lead candidates, which have solubility issues during formulation development.

“We are very pleased to have struck this collaboration with the team at XenoGesis,” said Frank Condella, president and chief executive officer at Molecular Profiles’ parent company, Columbia Laboratories. ”We have complementary service offerings which allow us to apply a science-driven, collective approach to overcome the complexities of challenging molecules. It also adds a vital pK service to our enabling technologies package.

“For us, this will build-upon the very successful drug development alliances we already have in place. We can now seamlessly offer a comprehensive service from initial drug discovery through to clinical supplies with best-in-class companies,” concluded Mr. Condella.

XenoGesis was founded by its managing director, Richard Weaver Ph.D., after a 15-year career at AstraZeneca. The company specializes in studying research compounds from a chemical and biological perspective to inform clients on how they will behave in the body.

Dr. Weaver commented, “Combining our skills in DMPK with the chemical knowledge at Molecular Profiles will provide a solid platform to support clients.  We will be able to give them a better understanding of their compounds during pre-clinical work, which in turn, will reduce cost and provide a quicker route to market.”

Working with leading drug development companies across the world, Columbia Laboratories’ Molecular Profiles subsidiary specializes in advanced characterisation, pharmaceutical product development, clinical trials manufacturing and analytical support.

The company recently created a new enabling technologies team and invested in GMP hot melt extrusion (HME) technology at its clinical manufacturing facility to further enhance its expertise in the processing of difficult-to-progress molecules.

Alongside its development capabilities, its MHRA-licensed site enables the company to manufacture a range of dosage forms for clinical trials spanning solids, liquids, semi-solids and inhaled products, including potent compounds and controlled drugs.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.
Substance Can Potentially Postpone Aging
Researchers bridge the gap between two main aging theories - repairs to the DNA and poor functioning mitochondria.
Untangling Cause Of Memory Loss In Neurodegenerative Diseases
NIH-funded mouse study identifies a possible therapeutic target for a family of disorders.
New Model for Understanding Human Myeloma
Researchers develop mouse model where mice carry six human genes involved in human tumour growth.
Preventing Alzheimer's in Mice
Researchers have prevented the Alzheimer’s development in mice by using a virus delivery system to transport a specific gene into the brain.
New Platform for Roundworms Could Speed Up Drug Delivery
Researchers have developed a large-scale in vitro drug discovery platform that could speed up scientific research.
Scientists Speed Up Muscle Repair
Researchers discovered genetically modified mice were able to support far more regenerative stem cells, for muscle repair, than previously thought.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos